soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Heart disease is the #1 cause of death in type 2 diabetes — and for the first time, an GLP-1 drug has been proven to reduce major events The The SOUL Study - by

New research suggests people taking these medications may not be getting enough guidance on protein, vitamins, and overall diet quality, increasing the risk of muscle loss and nutrient deficiencies.

They helped identifyGLP-1 and GLP-2, and demonstrated how boosting GLP-1 levels could improve insulin response

NRD per 1000 people 5.57 (6.61 to 4.53)), cannabis use (0.86 (0.81 to 0.90), NRD 2.25 (3.00 to 1.50)), cocaine use (0.80 (0.72 to 0.88), NRD 0.97 (1.37 to 0.57)), nicotine use (0.80 (0.74 to 0.87), NRD 1.64 (2.19 to 1.09)), and opioid use (0.75 (0.67 to 0.85), NRD 0.86 (1.19 to 0.52)), and other SUDs (0.87 (0.81 to 0.94), NRD 1.12 (1.68 to 0.55)) and composite outcome of all incident SUDs (0.86 (0.83 to 0.88), NRD 6.61 (7.95 to 5.26))

Ecuador Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market analysis offers a comprehensive overview of industry trends, market dynamics, and strategic growth opportunities for global stakeholders.